Literature DB >> 29434984

Antitumor effect of membrane-type Tim-3 on hepatocellular carcinoma Hepa1-6 cells of ICR mice.

Ju Liu1, Haiying Sun1, Dan Shen1, Mingmin Wang1, Zirong Wen1.   

Abstract

In the present study, the inhibitory effect of transmembrane Tim-3 on hepatocellular carcinoma Hepa1-6 cells and the potential application of Tim-3 on immune system of Institute of Cancer Research (ICR) mice loaded with Hepa1-6 hepatocellular carcinoma was investigated. The animal model was established via inoculation of Hepa1-6 hepatocarcinoma cells at the hind thigh of ICR mice. Recombinant vector plasmids were transfected at the same site for gene therapy by injection to observe the inhibitory effect of Tim-3 on tumor growth. A panel of genes from tumor tissues at various time intervals was analyzed by reverse transcription-polymerase chain reaction. Flow cytometry was used to evaluate the proliferation and cytotoxicity of splenocytes after Tim-3 transfection. Synergistic effects of Tim-3 with tumor abnormal protein-1 (TAP1) was also studied. It was revealed that the growth of tumor was significantly suppressed after the transfection of Tim-3. In the presence of Tim-3, the proliferation of splenocytes and cytolysis in the early phase of tumor development was significantly enhanced, and this antitumor effect was further improved by the synergistic effect of Tim-3 with TAP1. Therefore, the membrane-type Tim-3 may behave as an effective immunoregulator to enhance antitumor immune responses. Furthermore the present findings suggest that antitumor immunity was improved by the combined effect of Tim-3 and TAP1.

Entities:  

Keywords:  Hepa1-6 hepatocarcinoma; IL-13; TAP1; Tim-3; antitumor immunity

Year:  2017        PMID: 29434984      PMCID: PMC5777340          DOI: 10.3892/ol.2017.7620

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  18 in total

1.  Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance.

Authors:  Catherine A Sabatos; Sumone Chakravarti; Eugene Cha; Anna Schubart; Alberto Sánchez-Fueyo; Xin Xiao Zheng; Anthony J Coyle; Terry B Strom; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2003-10-12       Impact factor: 25.606

2.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity.

Authors:  Rachel H McMahan; Lucy Golden-Mason; Michael I Nishimura; Brian J McMahon; Michael Kemper; Todd M Allen; David R Gretch; Hugo R Rosen
Journal:  J Clin Invest       Date:  2010-11-15       Impact factor: 14.808

4.  Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure.

Authors:  Güliz Kozdağ; Gökhan Ertaş; Teoman Kiliç; Eser Acar; Ayşen Ağir; Tayfun Sahin; Metin Cetin; Ulaş Bildirici; Dilek Ural
Journal:  Med Sci Monit       Date:  2010-03

5.  Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.

Authors:  Shigeki Chiba; Muhammad Baghdadi; Hisaya Akiba; Hironori Yoshiyama; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Yoichiro Fujioka; Yusuke Ohba; Jacob V Gorman; John D Colgan; Mitsuomi Hirashima; Toshimitsu Uede; Akinori Takaoka; Hideo Yagita; Masahisa Jinushi
Journal:  Nat Immunol       Date:  2012-07-29       Impact factor: 25.606

6.  Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response.

Authors:  Sharvan Sehrawat; Pradeep B J Reddy; Naveen Rajasagi; Amol Suryawanshi; Mitsuomi Hirashima; Barry T Rouse
Journal:  PLoS Pathog       Date:  2010-05-06       Impact factor: 6.823

7.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.

Authors:  Kaori Sakuishi; Lionel Apetoh; Jenna M Sullivan; Bruce R Blazar; Vijay K Kuchroo; Ana C Anderson
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

8.  T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis.

Authors:  Mohsen Khademi; Zsolt Illés; Alexander W Gielen; Monica Marta; Naruhiko Takazawa; Claire Baecher-Allan; Lou Brundin; Jan Hannerz; Claes Martin; Robert A Harris; David A Hafler; Vijay K Kuchroo; Tomas Olsson; Fredrik Piehl; Erik Wallström
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

9.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

10.  Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection.

Authors:  Ali Sakhdari; Shariq Mujib; Bahareh Vali; Feng Yun Yue; Sonya MacParland; Kiera Clayton; Richard Bradley Jones; Jun Liu; Erika Yue Lee; Erika Benko; Colin Kovacs; Jennifer Gommerman; Rupert Kaul; Mario A Ostrowski
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

View more
  1 in total

1.  Dynamic proteomic change of tumor and immune organs in an immune-competent hepatocellular carcinoma mouse model.

Authors:  Jiaqi Jiao; Linlin Ji; Xianju Li; Zhan Gao; Guangshun Wang; Jun Qin; Yini Wang; Yi Wang
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.